|
CAS
|
521-74-4
|
|
中文名称
|
溴羟喹啉
|
|
英文名称
|
Broxyquinoline
|
|
别名
|
5,7-二溴-8-氧化喹啉
|
|
纯度
|
≥98%
|
|
分子式
|
C9H5Br2NO
|
|
分子量
|
302.95
|
|
外观（性状）
|
Yellow to brown Solid
|
|
储存条件
|
Powder : -20℃, 2 years;In solvent(母液): -20℃, 1 month; -80℃, 6 months
|
|
溶解性
|
Soluble in DMSO ≥1mg/mL;Soluble in Water < 0.1mg/mL
|
|
EC
|
EINECS 208-317-8
|
|
MDL
|
MFCD00006785
|
|
InChIKey
|
ZDASUJMDVPTNTF-UHFFFAOYSA-N
|
|
InChI
|
InChI=1S/C9H5Br2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
|
|
PubChem CID
|
2453
|
|
SMILES
|
OC1=C2N=CC=CC2=C(Br)C=C1Br
|
|
描述
|
Broxyquinoline是一种抗原虫化合物。(Broxyquinoline is an antiprotozoal compound.)
|
|
靶点
|
Parasite
|
|
通路
|
Anti-infection
|
|
生物活性
|
Broxyquinoline (Dibromohydroxyquinoline) is a potent severe fever with thrombocytopenia syndrome virus (SFTSV) inhibitor with an IC50 of 5.8 μM. Broxyquinoline is an antiprotozoal agent[1-2].
|
|
In Vitro
|
Four compounds displayed efficacies against parasite growth in vitro with low micromolar IC(50) values. The effective compounds were broxyquinoline (IC(50) 64.9 μM), cloxyquin (IC(50) 25.1 μM), cloxacillin sodium (IC(50) 36.2 μM) and sodium dehydrocholate (IC(50) 53.2 μM).[2]
|
|
数据来源文献
|
[1]. Shuofeng Yuan, et al. Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus. Viruses. 2019 Apr 25;11(4):385.
[2]. Fritzler JM, et al. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). J Antimicrob Chemother. 2012 Mar;67(3):609-17.
|
|
规格
|
100mg 250mg
|
|
单位
|
瓶
|
